Olaparib

Generic Name: Olaparib

Brand Names: Lynparza

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃FN_₄O_₃

CAS Number: 763113-22-0

Unique Ingredient Identifier: WOH1JD9AR8

Background: Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...

Indication: Ovarian cancer

Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions: Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer

Associated Therapies: Maintenance therapy

Clinical Trials

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4

Active, not recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: olaparib
Drug: enzalutamide
Drug: abiraterone acetate
Drug: Prednisone

First Posted Date: 2022-07-13

Last Posted Date: 2024-11-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 43

Registration Number: NCT05457257

Locations: 🇨🇳
Research Site, Zhengzhou, China

Pilot Trial for Treatment of Recurrent Glioblastoma

Early Phase 1

Recruiting

Conditions: Recurrent Glioblastoma
Glioblastoma
Recurrent Disease

Interventions: Drug: Afatinib
Drug: Dasatinib
Drug: Palbociclib
Drug: Everolimus
Drug: Olaparib

First Posted Date: 2022-06-27

Last Posted Date: 2024-06-03

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 10

Registration Number: NCT05432518

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Phase 2

Active, not recruiting

Conditions: Locally Advanced Uterine Corpus Leiomyosarcoma
Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
Stage III Uterine Corpus Leiomyosarcoma AJCC v8
Metastatic Uterine Corpus Leiomyosarcoma
Unresectable Uterine Corpus Leiomyosarcoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Drug: Olaparib
Drug: Pazopanib
Drug: Temozolomide
Drug: Trabectedin
Procedure: Transthoracic Echocardiography

First Posted Date: 2022-06-27

Last Posted Date: 2024-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 190

Registration Number: NCT05432791

Locations: 🇺🇸
Epic Care-Dublin, Dublin, California, United States
🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 143 locations

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1

Recruiting

Conditions: Stage III Pancreatic Cancer AJCC v8
Locally Advanced Pancreatic Carcinoma
Stage II Pancreatic Cancer AJCC v8
Unresectable Pancreatic Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Biological: Durvalumab
Drug: Olaparib
Radiation: Radiation Therapy
Procedure: Radiologic Examination

First Posted Date: 2022-06-09

Last Posted Date: 2024-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT05411094

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 8 locations

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: RP-3500
Drug: Olaparib

First Posted Date: 2022-06-06

Last Posted Date: 2024-11-11

Lead Sponsor: University of Utah

Target Recruit Count: 5

Registration Number: NCT05405309

Locations: 🇺🇸
Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Phase 2

Recruiting

Conditions: Gastric Cancer
GastroEsophageal Cancer

Interventions: Drug: Pembrolizumab
Drug: Olaparib
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2022-05-18

Last Posted Date: 2024-11-26

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 26

Registration Number: NCT05379972

Locations: 🇺🇸
University of Colorado Health, Aurora, Colorado, United States
🇺🇸
UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States
🇺🇸
UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States

and more 1 locations

Pembrolizumab Plus Olaparib in LA-HNSCC

Phase 2

Recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Biological: Pembrolizumab
Drug: Olaparib
Drug: Cisplatin
Radiation: IMRT (intensity modulated radiation therapy)

First Posted Date: 2022-05-09

Last Posted Date: 2024-02-14

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT05366166

Locations: 🇺🇸
UNC Lineberger, Chapel Hill, North Carolina, United States
🇺🇸
University of Louisville, Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸
Medical University of South Carolina (MUSC), Charleston, South Carolina, United States

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Olaparib

First Posted Date: 2022-04-22

Last Posted Date: 2023-04-18

Lead Sponsor: SOLTI Breast Cancer Research Group

Target Recruit Count: 63

Registration Number: NCT05340413

Locations: 🇪🇸
H. C. U. Valencia, Valencia, Spain
🇪🇸
H. San Cecilio, Granada, Spain
🇪🇸
H Clinic de Barcelona, Barcelona, Spain

and more 2 locations

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Phase 2

Recruiting

Conditions: Early-stage Breast Cancer

Interventions: Drug: Atezolizumab 1200 mg in 20 ML Injection
Drug: Trastuzumab/pertuzumab
Drug: Inavolisib
Drug: Ipatasertib
Drug: Olaparib
Drug: Sacituzumab govitecan

First Posted Date: 2022-04-18

Last Posted Date: 2023-07-06

Lead Sponsor: German Cancer Research Center

Target Recruit Count: 240

Registration Number: NCT05332561

Locations: 🇩🇪
Universitätsklinikum Ulm, Ulm, Bayern, Germany
🇩🇪
Universitätsklinikum Carl-Gustav-Carus, Dresden, Sachsen, Germany
🇩🇪
National Center for Tumor Diseases, Heidelberg, Baden-Wuerttemberg, Germany

and more 2 locations

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Early Phase 1

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Olaparib

First Posted Date: 2022-04-11

Last Posted Date: 2023-10-03

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 20

Registration Number: NCT05320757

Locations: 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy